Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Ala

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The EMBO Journal|May 15, 1995
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptorB Chini, B Mouillac, Y Ala, et al.
Cancer Gene Therapy|August 11, 2001
HSV-tk gene therapy for human renal cell carcinoma in nude miceK J Pulkkanen, J J Parkkinen, J M Laukkanen, et al.
Molecular Cancer Therapeutics|February 20, 2007
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivoMaria Rajecki, Anna Kanerva, Ulf-Håkan Stenman, et al.
European Journal of Pharmacology|July 23, 1997
Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptorsY Ala, D Morin, E Mahé, et al.
Journal of the American Society of Nephrology : JASN|October 17, 1998
Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotypeY Ala, D Morin, B Mouillac, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The EMBO Journal|May 15, 1995
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptorB Chini, B Mouillac, Y Ala, et al.
Cancer Gene Therapy|August 11, 2001
HSV-tk gene therapy for human renal cell carcinoma in nude miceK J Pulkkanen, J J Parkkinen, J M Laukkanen, et al.
Molecular Cancer Therapeutics|February 20, 2007
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivoMaria Rajecki, Anna Kanerva, Ulf-Håkan Stenman, et al.
European Journal of Pharmacology|July 23, 1997
Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptorsY Ala, D Morin, E Mahé, et al.
Journal of the American Society of Nephrology : JASN|October 17, 1998
Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotypeY Ala, D Morin, B Mouillac, et al.
Pageof 2